Have any questions? 706-721-6582 or cts@augusta.edu
- GSK 205744: A Phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult subjects with IPSS-R high and very high risk myelodysplastic syndromes (MDS) previous treated with hypomethylating agents (HMA)
Clinical Trial
GSK 205744: A Phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult subjects with IPSS-R high and very high risk myelodysplastic syndromes (MDS) previous treated with hypomethylating agents (HMA)
The purpose of this study is to test the safety of the study drug, GSK525762, and how well it works in treating myelodysplastic syndrome (MDS) when given by itself and when combined with another drug called azacitidine.
Eligibility Criteria
- 1. 18 years old and greater (at the time of written consent) 2. Must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by WHO classification 3. Must have failed hypomethylating treatment 4. Must have failed or are not a candidate for allogeneic stem cell transplantation
RESEARCH. INNOVATION. DISCOVERY.